HIGHLIGHTS
- who: Hannes Treiber from the Department of Hematology and Medical Oncology, University Medicine Gu00f6ttingen, Robertu2011Kochu2011Strau00dfe, Gu00f6ttingen, Germany have published the research work: Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity, in the Journal: (JOURNAL) of March/31,/2021
- what: The aim of this study was to obtain real-world data on feasibility, efficacy, and toxicity of regorafenib in high-grade glioma patients. The aim was to collect data about safety, toxicity, and treatment adherence.
- how: For the primary outcome survival data were analyzed by Kaplan-Meier . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.